HEALTH PROFESSIONAL · SOURCE READING

Sorafenib

Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 13, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs / Additional TKI therapy options

Sorafenib is a multitarget kinase that is similar in structure and mechanism to regorafenib. A phase II trial of patients with imatinib- and sunitinib-resistant GISTs showed that sorafenib offered potential benefit, with a disease control rate of 68% and a median PFS of 5 months.[45]

Source links and citations

Preserved source evidence · Not medical advice